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Background: Studies have shown that delayed treatment of several non-hepatobiliary (HB) malignan-
cies is associated with adverse effects on disease progression and survival. Delayed treatment of HB
malignancies has not been thoroughly investigated.
Methods: We performed a retrospective institutional review of patients referred to the Hepatobiliary
Surgery Service at Beth Israel Deaconess Medical Center (BIDMC) for hepatobiliary malignancies from
2002 to 2008. Primary outcomes included the time delays (TD) in patient workup. Secondary outcomes
were reasons for delay as well as disparities in TD based on demographic factors.
Results: Multivariate-adjusted linear regression showed a significant trend of increasing time from
presentation until referral to a HB surgeon over the 7-year period (P = 0.001). There were no differences
in TD by gender, age or education level. Multivariate-adjusted linear regression showed a significant trend
of increasing number of imaging tests performed prior to referral [computerized tomography (CT),
magnetic resonance imaging (MRI), positron emission tomography (PET) and ultrasound and endoscopic
ultrasound (US/EUS)] (P < 0.001). Multivariate-adjusted linear regression in resectable patients showed a
significant difference in overall length of survival in those with a TD1 > 30 days compared with those with
a TD1 (TD from presentation until referral) <30 days (P = 0.042).
Conclusions: Delays were associated with an increase in imaging studies and delays adversely affect
survival in resected patients. Referring physicians are encouraged to expedite the evaluation and early
referral of all patients to an HB surgeon for evaluation and treatment.
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Introduction
Annually in the United States, there are approximately 15 000 new
cases of hepatobiliary (HB) malignancies resulting in significant
morbidity and nearly 12 000 deaths.1 Currently there is little data
examining time delays (TD) in the care of patients with HBmalig-
nancies and their effects on patient outcomes. Furthermore there
is no consensus on what constitutes a significant TD for cancer
patients, although some expert reviews have suggested that a time
between presentation and referral for definitive treatment of >30
days is unreasonable and therefore should be defined as constitut-
ing a delay in treatment.2 Delayed treatment of many non-HB
malignancies is associated with negative effects on survival and
disease progression.3–9 Treatment delay in hepatocellular carci-
noma (HCC) of >3 months has been associated with tumour
progression and decreased survival rates.10 A delay in treatment
of pancreatic cancer has been associated with a lower probability
of resectability.11 As surgery provides the only possibility of a cure,
it is important that patients are seen for surgical assessment in a
timely fashion.
Previous studies have investigated reasons for delay in cancer
patients and have suggested lack of concrete follow-up times or
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long waiting times for investigations as several possible factors.12
While it is necessary to perform appropriate investigations to
adequately assess the presence and clinical stage of hepatobiliary
malignancies, these tests should not inordinately delay referral to
HB surgeons so that access to potentially curative procedures can
be performed. Our institution has noticed more patients present-
ing for surgical evaluation over 3 months after their initial pre-
sentation. The aim of the present study was to examine if there
has, in fact, been an increase in TD from 2002 to 2008, to identify
possible reasons for these delays and to determine if any dispari-
ties in TD based on demographic and socioeconomic factors exist.
Materials and methods
After approval from the BIDMC Institutional Review Board a
retrospective review was performed on all patients (n = 350) who
were referred to the Hepatobiliary Surgery Service at Beth Israel
Deaconess Medical Center (BIDMC) in Boston, MA, USA,
for hepatobiliary malignancies between 1 January 2002 and 31
October 2008. Patients with non-malignant diagnoses were
excluded. Both patients who did not and those who did go on to
receive surgical treatment were included. Patients were identified
from a database maintained in the Transplant Institute. The paper
charts and electronic medical records of all patients were
reviewed. HP malignancies were defined as having a diagnosis of
cholangiocarcinoma, pancreatic cancer, gallbladder cancer, hepa-
tocellular carcinoma (HCC) and secondary malignant neoplasms
of the liver (e.g. colon, breast, ovarian, pancreatic, etc.). We ex-
amined age, gender, race, education background, diagnosis, and
number and type of imaging studies performed. The primary
outcomes were TD in patient workup. TD were divided into three
intervals: TD from presentation until referral (TD1), TD from
referral until seen by an HB surgeon (TD2) and TD from being
seen by an HB surgeon until surgery (TD3). Secondary outcomes
were reasons for delay as well as disparities in TD based on demo-
graphic factors. Imaging tests were defined as computerized
tomography (CT), magnetic resonance imaging (MRI), positron
emission tomography (PET), ultrasound (US) and endoscopic
ultrasound (EUS). The number of imaging tests (CT, MRI, PET
and US/EUS) performed between presentation and referral to
an HB surgeon was examined. Time between presentation and
referral (TD1) >30 days was defined as constituting a delay in
diagnosis. Patients who had time delay >30 days were examined
to determine the reasons for delay. The reasons for delay were
assigned to one of five categories: external workup, internal
(BIDMC) workup, chemotherapy, medical factors and patient
factors. Overall length of survival from the date of presentation
was determined for all patients by both chart review and from the
Social Security Death Index (SSDI) at http://www.rootsweb.com.
Statistical analyses were performed using STATA version 10.0
software (STATA Corp. College Station, TX, USA). Statistical tests
included multivariate-adjusted linear regression or multivariate-
adjusted logistic regression. All statistical tests adjusted for
the following parameters: age, gender, race, education status
and cancer diagnosis. Time delays were log-transformed in the
analysis.
Results
A total of 350 patients with HB malignancies were referred to
Hepatobiliary Surgery Service. Patient characteristics are summa-
rized in Table 1. The median time from presentation until referral
to an HB surgeon (TD1) by year can be seen in Fig. 1. The median
TD1 over the 7-year period was 33 days.A total of 163 patients had
a TD1 greater >30 days (46.6%).The median time from referral
until being seen by an HB surgeon (TD2) was 6 days. The median
time from being seen by an HB surgeon until surgery (TD3)
was 16 days. These delays reflect patients requiring further
intervention pre-operatively such as percutaneous transhepatic
cholangiography for cholangiocarcinoma patients, portal vein
embolization for patients undergoing extensive hepatic resection
or patients on chemotherapy (e.g. Avastin) in whom a delay in
surgery is necessary.
Multivariate-adjusted linear regression showed a significant
trend of increasing time from presentation until referral to an HB
surgeon (TD1) from 2002 to 2008 (P = 0.001). Sensitivity analysis
was performed by removing all extreme outliers (TD1 > 250 days)
and then repeating the analysis; all significant trends were still
present. There was no change in time from referral until being
seen by an HB surgeon (TD2), and time from being seen by an HB
surgeon until surgery (TD3) from 2002 to 2008. Non-significant
trends for prediction of time delay between presentation and
referral included Black/African American race (P = 0.085) and
Latino race (P = 0.068). There were no significant differences
in time delay by gender, age or education level. The number and
types of cancer diagnosis can be seen in Table 1. There was no
significant difference in TD in patients with cholangiocarcinoma,
pancreatic cancer, gallbladder cancer and hepatocellular carci-
noma. A secondary neoplasm of the liver was associated with
an increased TD between presentation and referral (TD1)
(P = 0.007).
Multivariate-adjusted linear regression showed a significant
trend of increasing number of imaging tests from 2002–08
(P < 0.001). The mean number of tests by year can be seen in
Fig. 2. The mean number of imaging tests per patient over the
7-year period was 2.12 (1.14) (Table 2). The mean number of
imaging tests in patients whose TD was <30 days was 1.68
(0.899). The mean number of imaging tests in patients whose
TD was >30 days was 2.52 (1.16). The difference between these
two groups was statistically different (P < 0.001).
Patients who had time delay >30 days were examined to deter-
mine the reason for delay. The reason for delay was categorized
into five categories: external workup, internal (internal BIDMC)
workup, chemotherapy, medical factors and patient factors.When
the proportion of patients within each of the five categories was
compared from year to year there were no significant differences
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in the proportions of patients within each of the five categories,
respectively.
While the proportion of patients within the external workup
group did not change over the 7 years, there was a significant
increase in time from presentation until referral (TD1) within this
group over the 7-year period (P < 0.05). The requirement for
imaging to be repeated after first being seen by an HB surgeon was
examined with multivariate-adjusted logistic regression. There
was no change in the odds of repeat imaging over the 7-year
period.
Multivariate-adjusted logistic regression did not show a dif-
ference in the odds of resectability with increasing time
from presentation until referral to an HB surgeon. Multivariate-
adjusted linear regression in resectable patients showed a
significant difference in survival in those with a TD1 greater
than 30 days compared with those with a TD1 less than
30 days (P = 0.042). A non-significant trend of increasing
stage of disease was seen in those with a TD1 greater than
30 days compared with those with a TD1 less than 30 days
(P = 0.065).
Discussion
Previous guidelines have set 4 weeks as the maximum time needed
to diagnose cancer after a patient presenting to their family
physician.2 It is clear from our data that a significant number of
patients are not being referred within this time frame and that this
number of patients has increased over the past 7 years. In particu-
lar there was a noticeable jump in delay times (TD1) between 2004
and 2005. The drop in delay times from 2007 to 2008 may be a
result of the fact that some patients who presented in 2008 had
Table 1 Patient demographics
Age at
presentation
Mean SD Min Max
61.1 12.928 21.95 89.42
N = 350 Percent
Gender Female 153 43.71
Male 197 56.29
Race Asian 35 10
Black/African-American 17 4.86
Caucasian 266 76
Hispanic or Latino 8 2.29
Other 4 1.14
Unknown 20 5.71
Education <High School 20 5.71
High School 63 18
College 94 26.86
Graduate/Professor degree 23 6.57
Unknown 150 5.71
Diagnosis Cholangiocarcinoma 68 19.43
Intrahepatic Cholangiocarcinoma 8 2.29
Pancreatic head cancer 32 9.14
Pancreatic body cancer 2 0.57
Gallbladder cancer 20 5.71
Hepatocellular carcinoma 83 23.71
Secondary malignant neoplasm liver (colon) 76 21.71
Secondary malignant neoplasm liver (other) 43 12.29
Other 18 5.14
Table 2 Number of imaging tests by year
Year Mean number of
imaging tests
SD
<2002 1.29 0.76
2002 1.63 1.05
2003 1.96 1.04
2004 1.88 1.00
2005 2.20 1.12
2006 2.53 1.14
2007 2.44 1.20
2008 2.50 1.21
Total 2.12 1.14
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still not been referred on to an HPB surgeon at the time the study
was conducted. This would particularly be the case for those with
a long delay time.
Themean TD is longer than the median in each year, suggesting
that our data is positively skewed.
Previous authors have shown that most delays in cancer
diagnosis occur outside the hospital and split between general
practitioner and patient delay.13 As our data shows the number
of investigations being performed prior to referral has also
increased over this time period and could certainly be a major
contributor to this delay. Patients with delays >30 days had a
statistically significant higher number of imaging tests being per-
formed. Previous authors have suggested waiting times for inves-
tigations as a major source of delay in malignancy workup.12
Investigations are clearly necessary prior to referral particularly
in patients with atypical presentations, but must be undertaken
in a timely manner to avoid delay. General practitioners may feel
pressure to have a definitive diagnosis prior to referral on to an
HPB specialist. However, if initial scans reveal a lesion that will
ultimately lead to referral, then a referral should be placed and
the need for further diagnostic tests can be made by the specialist
themselves.
Predetermined follow-up appointments must be made to
ensure that workup is as efficient as possible and once a malignant
diagnosis is likely an urgent surgical specialist referral should
be made.
While delay times increased for all patients a non-significant
trend of delay was evident in minorities such as Blacks and
Latinos. Previous studies have found Black HCC patients have
more advanced tumour stage at diagnosis and lower rates of both
surgical interventions and survival.14 Delayed referral for surgery
has been suggested as a possible contributor to this disparity. We
did not find any difference in time delay by education status;
however, we had a significant amount of missing information.
Despite attempts to address inequalities in patient care it appears
that there continues to be disparities in referral times by race.
TD has been shown to be correlated with disease progression in
several non-HB cancers as well as with HCC and pancreatic cancer
in previous studies.3–11 While the present study did not show
a significant difference in resectability with longer time delay
(TD1), the biological nature of the HPB tumours studied would
leave one to speculate that disease progression is inevitable with
lengthy delays. It is possible that our data has some unmeasured
confounding as a result of the retrospective nature of this study.
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Figure 1 Time delay (TD) between presentation and referral to an HB surgeon (TD1) by year
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Figure 2 Number of imaging tests by year
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In those patients who were resectable, a significant difference
in survival in those with a TD1 > 30 days compared with those
with a TD1 < 30 days was observed. A non-significant trend of
increasing stage of disease was seen in those with a TD1 > 30 days
compared with those with TD1 < 30 days. It is possible, therefore,
that while delays may not immediately effect resectability, they
ultimately lead to reduced survival in those who are resected.
In conclusion, in our institution there has been a significant
trend of increasing time from initial presentation until referral to
an HB surgeon over the past 7 years. There has been an increase in
the number of imaging tests prior to referral. Patients with delays
>30 days had a statistically significant higher number of imaging
tests being performed. A significant difference in survival in those
with a TD1 > 30 days compared with those with a TD1 < 30 days
has also been shown. While it is necessary to perform an investi-
gation to adequately assess presence and stage of hepatobiliary
cancer, these tests should not delay referral on to HPB surgeons so
that access to potentially curative procedures can be performed.
Once general practitioners determine that a patient has a lesion
that will ultimately lead to referral, then a referral should be placed
and the need for further diagnositic tests can be made by the
specialist themselves. The information in the present study will be
used to help in streamlining the time from initial presentation
until referral on to HB surgeons in order to give patients the best
opportunity of a cure.
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